May. 2 at 12:19 PM
$VIR The arbitration was filed on April 16, 2026. Surprisingly, the stock did not crash.The Softening Deal: On the exact same day Brii filed for arbitration, Vir announced the closing of a massive global collaboration deal with Astellas Pharma for a prostate cancer drug (VIR-5500). This deal secured Vir
$240 million in upfront cash and a
$75 million equity investment.The Resulting Price Movement: The influx of massive non-dilutive funding from Astellas heavily countered the negative legal news.April 16: Stock closed at
$10.33.APRIL 20: Hit a peak of
$11.09 (approaching a 52-week high) as investors celebrated the cash infusion.Late April: Pulled back slightly to settle around
$10.00 as the long-term uncertainty of the Brii arbitration and general market movements set in.
